Sanofi has continued to make progress in the development of Icaria (isatuximab), with the company announcing that the therapy met its primary endpoint in combination with pomalidomide and low-dose dexamethasone in the treatment of relapsed/refractory multiple myeloma compared to the standard care.
Ook interessant voor je
